阅读说明：本技术 对携带酪氨酸激酶抑制剂抗性egfr突变的癌细胞具有抗肿瘤活性的化合物 (Compounds with antitumor activity against cancer cells carrying tyrosine kinase inhibitor resistant EGFR mutations ) 是由 J·罗比丘 M·尼尔森 J·V·海马赫 于 2020-04-16 设计创作，主要内容包括：本公开提供了通过施用第二代喹唑啉胺衍生物类酪氨酸激酶抑制剂来治疗确定具有奥希替尼抗性EGFR突变的患者的癌症的方法。(The present disclosure provides methods of treating cancer in patients determined to have an axitinib-resistant EGFR mutation by administering a second generation quinazolinamine derivative tyrosine kinase inhibitor.)